Pryor 60mg Tablet

Like other anticancer medicines, Pryor 60mg Tablet has mild to severe side effects. These are undesired symptoms observed in the body after taking this tablet. Usually, they disappear with time as the body adjusts to the medicine. These adverse effects don't need special medical attention, but if you observe them continually, talk to your medical expert. Some of them are listed below:

Common side effects:
Fatigue
Diarrhea
Vomiting
Nausea
Joint and muscle pain
High blood pressure
Diabetes
Skin infections
Weight loss

Tiredness and dizziness

Severe Side effects:
Anemia
High cholesterol level
Heart diseases
Seizures
Bones fractures
Swelling in hand and feet

Pryor 60mg Tablet is a prescription-based anticancer drug that should be administered orally. It is advised to take this tablet after consulting your healthcare expert.

Pryor 60mg Tablet is an anticancer medicine that works by blocking the action of androgen receptors. These receptors are responsible for the growth of cancer cells. After some, cancer becomes resistant to hormonal treatments. In such situations, androgen receptors keep working and help in the multiplication of cancer cells. Pryor Tablet stops this process by blocking signals and preventing proteins from entering the cell’s nucleus, which stops the cancer cells from multiplying.

It is advised not to miss any scheduled dosage of Pryor 60mg Tablet. In case you miss a dose, consult your doctor immediately.

Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

Pryor 60mg Tablet is not recommended for patients having a history of heart disease, seizures, brain injury, or a recent stroke (within one year).

Your healthcare expert must measure your blood sugar & pressure, potassium level, and liver function tests at regular intervals. Taking the Pryor 60mg Tablet can cause fluctuations in their levels.

Use reliable methods of birth control and contraceptive pills to delay pregnancy while under treatment with Pryor 60mg Tablet. Discuss with your healthcare expert the risks and benefits of taking this medicine if you want to conceive in the future.

Hegele, A., Häußermann, R., Schultheis, S., Skrobek, L., Vink, M., Hollwegs, S. & Varughese, D. (2024). Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real-world data of a multicenter study. Journal of Cancer Research and Clinical Oncology, 150(9), 414.
Hussain, A., Jiang, S., Varghese, D., Appukkuttan, S., Kebede, N., Gnanasakthy, K., & Corman, S. (2022). Real-world burden of adverse events for apalutamide and enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States. BMC cancer, 22(1), 304.
Monge-Escartín, I., Gil, J., Carrera, C., Sáez-Peñataro, J., Ferrer, L., Aversa, C. & Vilaseca, A. (2024). Real-world study: Impact of multidisciplinary management of apalutamide-associated adverse events in prostate cancer. The Prostate.
Sánchez, J. C., Picola, N., Rodríguez‐Vida, A., Costa, M., Castañeda, D. M., Márquez, M. P. & Vilaseca, A. (2023). Apalutamide for prostate cancer: Multicentre and multidisciplinary real‐world study of 227 patients. Cancer Medicine, 12(24), 21969-21977.
Smith, M. R., Antonarakis, E. S., Ryan, C. J., Berry, W. R., Shore, N. D., Liu, G., & Rathkopf, D. E. (2025). Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort. European urology, 70(6), 963-970.
Tohi, Y., Kobayashi, K., Daizumoto, K., Sekino, Y., Fukuhara, H., Niigawa, H. & Sugimoto, M. (2025). Real-world clinical usage and efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer: a multi-institutional study in the CsJUC. Japanese Journal of Clinical Oncology, 55(6), 643-649.